AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,970,000 | -12.6% | 120,000 | 0.0% | 0.05% | -23.3% |
| Q2 2023 | $3,398,400 | +29.7% | 120,000 | +5.2% | 0.06% | +17.6% |
| Q1 2023 | $2,620,555 | +55.5% | 114,086 | +90.1% | 0.05% | +96.2% |
| Q4 2022 | $1,684,800 | -58.9% | 60,000 | -58.6% | 0.03% | -54.4% |
| Q3 2022 | $4,100,000 | -8.6% | 145,000 | -5.8% | 0.06% | +5.6% |
| Q1 2022 | $4,484,000 | +4.1% | 154,000 | +17.6% | 0.05% | +12.5% |
| Q4 2021 | $4,308,000 | -34.3% | 131,000 | +10.1% | 0.05% | -44.2% |
| Q2 2021 | $6,560,000 | +62.9% | 119,000 | +52.6% | 0.09% | -1.1% |
| Q1 2021 | $4,028,000 | -4.2% | 78,000 | -19.6% | 0.09% | -9.4% |
| Q4 2020 | $4,204,000 | +13.2% | 97,000 | -8.5% | 0.10% | +11.6% |
| Q3 2020 | $3,713,000 | -34.5% | 106,000 | 0.0% | 0.09% | -54.5% |
| Q2 2020 | $5,671,000 | +188.2% | 106,000 | +91.0% | 0.19% | +70.3% |
| Q1 2020 | $1,968,000 | -43.9% | 55,500 | -24.5% | 0.11% | -5.9% |
| Q4 2019 | $3,508,000 | -68.7% | 73,500 | -78.7% | 0.12% | -79.8% |
| Q3 2019 | $11,194,000 | – | 345,600 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 965,369 | $56,378,000 | 14.98% |
| Casdin Capital, LLC | 237,500 | $13,870,000 | 8.18% |
| BB BIOTECH AG | 2,839,528 | $165,828,000 | 5.42% |
| Opaleye Management Inc. | 130,000 | $7,592,000 | 3.78% |
| Redmile Group, LLC | 902,578 | $52,711,000 | 3.42% |
| Clarius Group, LLC | 109,230 | $6,379,000 | 2.63% |
| Opus Point Partners Management, LLC | 57,410 | $3,353,000 | 2.49% |
| Ghost Tree Capital, LLC | 125,000 | $7,300,000 | 1.36% |
| CAPITAL INTERNATIONAL LTD /CA/ | 346,937 | $20,261,000 | 1.32% |
| Eventide Asset Management | 300,800 | $17,567,000 | 1.16% |